左室功能减低的缺血性二尖瓣反流治疗选择
文章指出指南导向药物治疗是中度至重度患者的治疗选择,可考虑血运重建、二尖瓣手术、心脏再同步治疗或联合应用;经导管二尖瓣治疗适用于高危重度患者。多学科团队讨论对优化结局至关重要。
要点
- 指南导向药物治疗是中度至重度缺血性二尖瓣反流的治疗选择。
- 合适患者可考虑血运重建、二尖瓣手术、心脏再同步治疗或联合应用。
- 经导管二尖瓣治疗适用于高危重度反流伴心衰和左室射血分数减低者。
核心结论
- 二尖瓣手术和经导管二尖瓣治疗的作用仍在不断演变。
主要发现
- 缺血性二尖瓣反流治疗具有挑战性,常需多模式方法。
- 患者常合并多种共病,可能使手术不再可行。
- 多学科团队讨论对优化结局至关重要。
- 不同治疗选择具有不同获益和风险。
关键数值与推荐
- 指南导向的心衰药物治疗是中度至重度缺血性二尖瓣反流的治疗选择。
- 合适患者可考虑冠脉血运重建、二尖瓣手术、心脏再同步治疗或联合应用。
- 经导管二尖瓣治疗被认为适用于高危重度缺血性二尖瓣反流、心衰和左室射血分数减低的患者,尤其血流动力学不稳定者。
临床怎么用
- 对中度至重度缺血性二尖瓣反流患者应首先给予指南导向药物治疗。
- 在合适患者中考虑血运重建、二尖瓣手术、心脏再同步治疗或其组合。
- 高危重度患者伴心衰和左室射血分数减低时可考虑经导管二尖瓣治疗。
- 建议多学科团队讨论以优化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic mitral regurgitation is a condition characterized by mitral insufficiency secondary to an ischemic left ventricle. Primarily, the pathology is the result of perturbation of normal regional left ventricular geometry combined with adverse remodeling. We present a comprehensive review of contemporary surgical, medical, and percutaneous treatment options for ischemic mitral regurgitation, rigorously examined by current guidelines and literature. METHODS: We conducted a literature search of the PubMed database, Embase, and the Cochrane Library (through November 2018) for studies reporting perioperative or late mortality and echocardiographic outcomes after surgical and nonsurgical intervention for ischemic mitral regurgitation. RESULTS: Treatment of this condition is challenging and often requires a multimodality approach. These patients usually have multiple comorbidities that may preclude surgery as a viable option. A multidisciplinary team discussion is crucial in optimizing outcomes. There are several options for treatment and management of ischemic mitral regurgitation with differing benefits and risks. Guideline-directed medical therapy for heart failure is the treatment choice for moderate and severe ischemic mitral regurgitation, with consideration of coronary revascularization, mitral valve surgery, cardiac resynchronization therapy, or a combination of these, in appropriate candidates. The use of transcatheter mitral valve therapy is considered appropriate in high-risk patients with severe ischemic mitral regurgitation, heart failure, and reduced left ventricular ejection fraction, especially in those with hemodynamic instability. CONCLUSIONS: The role of mitral valve surgery and transcatheter mitral valve therapy continues to evolve.
引用
- Nappi F, Avtaar Singh SS, Padala M, et al. The Choice of Treatment in Ischemic Mitral Regurgitation With Reduced Left Ventricular Function. Ann Thorac Surg. 2019. PMID: 31445916. doi:10.1016/j.athoracsur.2019.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。